ActiveSight and Ambit Biosciences have that they have entered into a protein crystallography services agreement to advance Ambit's drug discovery program. The agreement covers the co-crystallization of Ambit proprietary molecules with proteins expressed by ActiveSight.
"We are delighted to provide Ambit, demonstrated leaders in the kinase arena, with structural biology support," stated Ronald V. Swanson, Ph.D., Chief Scientific Officer for ActiveSight.
"I am very pleased that we have initiated this technology collaboration in structural biology with ActiveSight," said Shripad Bhagwat, Sr. Vice President of Drug Discovery at Ambit. "This agreement is intended to accelerate Ambit's kinase drug discovery programs through the application of ActiveSight's protein crystallography technology applied across our discovery portfolio."